Effect of @entity905 on symptoms and gastric dysrhythmia in @entity1 with functional XXXX .

@entity1 @entity308 @entity905 @entity1109 @entity344 @entity2210
BACKGROUND/AIMS: Although antidepressants have been used for decades in treating @entity1 with functional abdominal syndromes, how they influence @entity344 remains unclear. We aimed to assess the role of @entity308 , and the effect of antidepressants on the functional @entity2210 @entity1 ' symptoms and gastric myoelectrical activity. METHODOLOGY: We conducted an open clinical trial with 40 functional @entity2210 @entity1 . Zung self-rating @entity308 scale was used in evaluating the @entity1 ' @entity308 . Cutaneous electrogastrography and evaluation of @entity344 were performed before and after administration of a one-month course of @entity905 . RESULTS: In the baseline study, the @entity308 functional @entity2210 @entity1 had higher symptom scores than non- @entity308 @entity1 (P < 0.05). The @entity308 functional @entity2210 @entity1 had higher percentages of tachygastria than healthy controls (P < 0.05), but the electrogastrography parameters of @entity308 and non- @entity308 functional @entity2210 @entity1 were not different. After one-month @entity905 treatment, the symptom scores improved significantly in the @entity308 functional @entity2210 @entity1 (P < 0.05), but not in the non- @entity308 @entity1 . Electrogastrography did not improve in either group. CONCLUSIONS: @entity308 functional @entity2210 @entity1 had higher symptom scores and responded well to @entity905 treatment. However, electrogastrography did not improve after the treatment. These findings suggest that @entity308 is significant in the presentation of @entity1109 , but not correlated with gastric myoelectrical activity.
